This may be advantageous for combinatorial therapies of PD-L1/PD-1 and cytotoxic T-lymphocyte associated antigen 4 blockades that would bring the activation and proliferation of effector T cells, thereby restoring the immune system toward attacking the tumor [50]. The gene discussed is PDCD1; the disease is neoplasm.